FindTrial
Sign In

To find out and compare the effectiveness of Kanaka Taila and Kumkumadi Taila nasya in the treatment of Vyanga (a skin disorder )

A randomised comparative clinical trail to evaluate the efficacy of Kanaka Tail nasya with Kumkumadi Tail nasya in Vyanga

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024755
Enrollment
68
Registered
2020-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue

Interventions

Intervention1: Kanaka Tail Nasya: Group A of 34 Patients having Vyanga will be administered with Kanaka Tail Nasya 6 Drops in Each Nostril for 7 Days Control Intervention1: Kumkumadi Tail Nasya: Group

Sponsors

PDEAs College of Ayurveda and Research Centre Akurdi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having classical symptoms of vyanga like tanu niruja shyava mandal on face of patient arha for nasya

Exclusion criteria

Exclusion criteria: Known case of systemic diseases vyanga either congenital or along with kushta known case of inflammatory disease of nose

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of kanaka tail nasya and kumkumadi tail nasya in the management of vyanga on the basis of subjective and objective parameters within 15 daysTimepoint: Daily assessment will be done for 7 days in the duration of nasya treatment and final assessment follow up will be done on 15th day with the window period of 5 days—

Secondary

MeasureTime frame
To study the adverse effects if anyTimepoint: For 7 days of nasya administration—

Countries

India

Contacts

Public ContactDr Sireesha Satyanarayana Popuri

PDEAs College of Ayurveda And Research Centre Akurdi

varsha.kale80@gmail.com9923800634

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026